Theravance Biopharma Inc TBPH
At closeSep 23, 2026, 4:00 PM EDT
After hours · Sep 23, 4:00 PM ET
- YTD
- -8.98%
- 1 year
- +58.71%
- Market cap
- 481.42M
- Revenue (ttm)
- 63.19M
- Profit margin
- -78.18%
- EPS (ttm)
- -1.03
- Shares out
- 49.17M
- P/E ratio
- 10.92
- Forward P/E
- 163.17
- YTD return
- -8.98%
- 1-year return
- +58.71%
- Volume
- 10.02M
- Avg volume
- 194.24K
- Open
- 17.06
- Previous close
- 17.03
- Day's range
- 17.02 – 17.07
- 52-week range
- 7.44 – 11.71
- Beta
- 0.25
- Price target
- 13.20 (-22.5%)
- Earnings date
- Feb 25, 2026
Key statistics
- Enterprise value
- 419.70M
- PEG ratio
- 0.00
- Price / sales
- 7.62
- Price / book
- 2.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.50%
- Free cash flow
- 0
- Total cash
- 91.36M
- Total debt
- 40.78M
- Return on equity
- -22.88%
- Short % of float
- 17.05%
- 50-day average
- 9.19
- 200-day average
- 8.90
Analyst view
- Target (low)
- 9.00
- Target (mean)
- 13.20
- Target (high)
- 21.00
- Strong buy1
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 25, 2026
Expected Feb 25, 2026. Consensus EPS estimate 0.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2026 | Dec 1, 2025 | 0.44 | — | — | — |
| Nov 10, 2025 | Sep 1, 2025 | — | 0.04 | +0.07 | +233.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 6, 2024 | TD Cowen | main | Hold | Hold |
| Aug 6, 2024 | Leerink Partners | down | Outperform | Market Perform |
| May 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- theravance.com
News
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition 
Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks - Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
This Vulcan Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday 
Crude Oil Surges Over 6%; Target Profit Tops Views 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Dow Dips 900 Points; Best Buy Posts Upbeat Earnings 
Jefferson Capital, Mobix Labs And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on TBPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROSHY ERAN | Director | Stock Award(Grant) | May 7, 2024 | 80,555 |
| FARNUM RHONDA | Officer | Sale | Nov 10, 2024 | 322,743 |
| GRANT JEREMY T | Director | Stock Award(Grant) | May 7, 2024 | 22,305 |
| GRAY SUSANNAH | Director | Stock Award(Grant) | May 7, 2024 | 31,488 |
| MITCHELL DEAN J | Director | Stock Award(Grant) | May 7, 2024 | 80,555 |
| O'CONNOR DONAL | Director | Stock Award(Grant) | May 7, 2024 | 63,555 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Madison Avenue Partners, LP | 19.34% | 9,511,150 | 93.11M | Sep 29, 2024 |
| Weiss Asset Management Lp | 15.16% | 7,457,060 | 73.00M | Sep 29, 2024 |
| Newtyn Management, Llc | 9.15% | 4,499,066 | 44.05M | Sep 29, 2024 |
| Blackrock Inc. | 7.59% | 3,731,305 | 36.53M | Sep 29, 2024 |
| Irenic Capital Management LP | 5.61% | 2,760,948 | 27.03M | Sep 29, 2024 |
| Vanguard Group Inc | 4.17% | 2,051,689 | 20.09M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.19% | 1,074,744 | 10.52M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.93% | 948,992 | 9.29M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.15% | 567,833 | 5.56M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.76% | 373,754 | 3.66M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.70% | 344,269 | 3.37M | Oct 30, 2024 |
| iShares Biotechnology ETF | 0.65% | 317,741 | 3.11M | Oct 30, 2024 |